Administration Updates / Coronavirus / Safety & Health

Phase 3 Clinical Trial of Investigational Vaccine for COVID-19 Begins

vaccineA Phase 3 clinical trial designed to evaluate if an investigational vaccine can prevent symptomatic coronavirus disease 2019 (COVID-19) in adults has begun. The vaccine, known as mRNA-1273, was co-developed by the Cambridge, Massachusetts-based biotechnology company Moderna, Inc., and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The trial, which will be conducted at U.S. clinical research sites, is expected to enroll approximately 30,000 adult volunteers who do not have COVID-19.

You can read more from the National Institutes of Health here.

If You Enjoy Articles Like This - Subscribe to the AMAC Daily Newsletter!

Sign Up Today
Notify of
Most Voted
Newest Oldest
Inline Feedbacks
View all comments
Bill Bryson
2 months ago

Be careful, I will “Not” take any [email protected] vaccine for this BS.

Would love your thoughts, please comment.x